tiprankstipranks
Advertisement
Advertisement
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
PremiumRatingsIcotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
1M ago
Icotyde label upside surprise for Protagonist, says H.C. Wainwright
Premium
The Fly
Icotyde label upside surprise for Protagonist, says H.C. Wainwright
1M ago
Protagonist announces Johnson & Johnson received approval for ICOTYDE
Premium
The Fly
Protagonist announces Johnson & Johnson received approval for ICOTYDE
1M ago
Protagonist Therapeutics price target raised to $95 from $93 at JPMorgan
PremiumThe FlyProtagonist Therapeutics price target raised to $95 from $93 at JPMorgan
2M ago
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
Premium
Company Announcements
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
2M ago
Protagonist Therapeutics price target raised to $100 from $90 at TD Cowen
Premium
The Fly
Protagonist Therapeutics price target raised to $100 from $90 at TD Cowen
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100